CN113491743B - Pharmaceutical composition for preventing and treating gout of birds and preparation method and application thereof - Google Patents
Pharmaceutical composition for preventing and treating gout of birds and preparation method and application thereof Download PDFInfo
- Publication number
- CN113491743B CN113491743B CN202110890080.2A CN202110890080A CN113491743B CN 113491743 B CN113491743 B CN 113491743B CN 202110890080 A CN202110890080 A CN 202110890080A CN 113491743 B CN113491743 B CN 113491743B
- Authority
- CN
- China
- Prior art keywords
- parts
- rhizoma
- preventing
- gout
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000005569 Gout Diseases 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 89
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 244000144977 poultry Species 0.000 claims abstract description 19
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 241000031023 Amana edulis Species 0.000 claims abstract description 17
- 241000723346 Cinnamomum camphora Species 0.000 claims abstract description 17
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 17
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 17
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 17
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 17
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 17
- 235000011477 liquorice Nutrition 0.000 claims abstract description 17
- 229960003080 taurine Drugs 0.000 claims abstract description 17
- 239000011719 vitamin A Substances 0.000 claims abstract description 17
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 17
- 229940045997 vitamin a Drugs 0.000 claims abstract description 17
- 241000903946 Clematidis Species 0.000 claims abstract description 16
- 241001673966 Magnolia officinalis Species 0.000 claims abstract description 16
- 239000001508 potassium citrate Substances 0.000 claims abstract description 16
- 229960002635 potassium citrate Drugs 0.000 claims abstract description 16
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims abstract description 16
- 235000011082 potassium citrates Nutrition 0.000 claims abstract description 16
- 235000018167 Reynoutria japonica Nutrition 0.000 claims abstract description 15
- 241001648835 Polygonum cuspidatum Species 0.000 claims abstract 4
- 230000000694 effects Effects 0.000 abstract description 25
- 230000001737 promoting effect Effects 0.000 abstract description 14
- 239000002994 raw material Substances 0.000 abstract description 14
- 210000003734 kidney Anatomy 0.000 abstract description 10
- 210000000952 spleen Anatomy 0.000 abstract description 10
- 208000004880 Polyuria Diseases 0.000 abstract description 8
- 230000035619 diuresis Effects 0.000 abstract description 8
- 239000004480 active ingredient Substances 0.000 abstract description 7
- 210000004185 liver Anatomy 0.000 abstract description 7
- 210000002700 urine Anatomy 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract 1
- 230000007613 environmental effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 44
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 32
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 27
- 229940116269 uric acid Drugs 0.000 description 27
- 229940079593 drug Drugs 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 15
- 235000013594 poultry meat Nutrition 0.000 description 15
- 239000012153 distilled water Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 238000002156 mixing Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 11
- 240000001341 Reynoutria japonica Species 0.000 description 11
- 238000005303 weighing Methods 0.000 description 11
- 241000271566 Aves Species 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 9
- 230000001603 reducing effect Effects 0.000 description 9
- 241000287828 Gallus gallus Species 0.000 description 8
- 235000013330 chicken meat Nutrition 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 229940126680 traditional chinese medicines Drugs 0.000 description 7
- 208000006820 Arthralgia Diseases 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 6
- 244000153955 Reynoutria sachalinensis Species 0.000 description 5
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- 230000029142 excretion Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000001503 joint Anatomy 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 230000009278 visceral effect Effects 0.000 description 5
- 244000281702 Dioscorea villosa Species 0.000 description 4
- 206010018634 Gouty Arthritis Diseases 0.000 description 4
- 241000972673 Phellodendron amurense Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 4
- 240000009022 Smilax rotundifolia Species 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 108010093894 Xanthine oxidase Proteins 0.000 description 4
- 102100033220 Xanthine oxidase Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 235000004879 dioscorea Nutrition 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- XMVONEAAOPAGAO-UHFFFAOYSA-N sodium tungstate Chemical compound [Na+].[Na+].[O-][W]([O-])(=O)=O XMVONEAAOPAGAO-UHFFFAOYSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 241000132012 Atractylodes Species 0.000 description 3
- 241000037740 Coptis chinensis Species 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010023232 Joint swelling Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 229960003459 allopurinol Drugs 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- QARYADFHOUHDSW-UHFFFAOYSA-M potassium 2H-oxazine-3-carboxylate Chemical compound O1NC(=CC=C1)C(=O)[O-].[K+] QARYADFHOUHDSW-UHFFFAOYSA-M 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- CMPGARWFYBADJI-UHFFFAOYSA-L tungstic acid Chemical compound O[W](O)(=O)=O CMPGARWFYBADJI-UHFFFAOYSA-L 0.000 description 3
- 150000007968 uric acids Chemical class 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 241001254604 Angelica pubescens Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 241000218158 Clematis Species 0.000 description 2
- 241000601164 Clematis orientalis Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 241000766380 Iphigenia Species 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 235000003805 Musa ABB Group Nutrition 0.000 description 2
- 240000008790 Musa x paradisiaca Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 235000015266 Plantago major Nutrition 0.000 description 2
- 244000299790 Rheum rhabarbarum Species 0.000 description 2
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 239000012445 acidic reagent Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 208000030175 lameness Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229910052808 lithium carbonate Inorganic materials 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 230000005982 spleen dysfunction Effects 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 229940032330 sulfuric acid Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- ZNOKGRXACCSDPY-UHFFFAOYSA-N tungsten trioxide Chemical compound O=[W](=O)=O ZNOKGRXACCSDPY-UHFFFAOYSA-N 0.000 description 2
- 150000007971 urates Chemical class 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- HDXIQHTUNGFJIC-UHFFFAOYSA-N (25R)-spirost-5-en-3beta-ol 3-O-<O-alpha-L-rhamnopyranosyl-(1-->2)-beta-D-glucopyranoside> Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O HDXIQHTUNGFJIC-UHFFFAOYSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000722953 Akebia Species 0.000 description 1
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000003717 Boswellia sacra Nutrition 0.000 description 1
- 235000012035 Boswellia serrata Nutrition 0.000 description 1
- 240000007551 Boswellia serrata Species 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- VNONINPVFQTJOC-RXEYMUOJSA-N Collettiside III Natural products O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 VNONINPVFQTJOC-RXEYMUOJSA-N 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 241000241550 Cyathula Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000005903 Dioscorea Nutrition 0.000 description 1
- 235000000504 Dioscorea villosa Nutrition 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 235000007710 Grifola frondosa Nutrition 0.000 description 1
- 240000001080 Grifola frondosa Species 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 235000019510 Long pepper Nutrition 0.000 description 1
- 241001571764 Lysimachia christinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091006688 Organic zwitterions/cation transporters Proteins 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 240000003455 Piper longum Species 0.000 description 1
- 235000003417 Plumeria rubra f acutifolia Nutrition 0.000 description 1
- 244000040691 Plumeria rubra f. acutifolia Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- IAPCTXZQXAVYNG-UHFFFAOYSA-M Potassium 2,6-dihydroxytriazinecarboxylate Chemical compound [K+].[O-]C(=O)C1=NC(=O)NC(=O)N1 IAPCTXZQXAVYNG-UHFFFAOYSA-M 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241001448535 Reineckea carnea Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 108091006735 SLC22A2 Proteins 0.000 description 1
- 108091006739 SLC22A6 Proteins 0.000 description 1
- 102100032417 Solute carrier family 22 member 2 Human genes 0.000 description 1
- 102100036930 Solute carrier family 22 member 6 Human genes 0.000 description 1
- 240000007284 Stenochlaena palustris Species 0.000 description 1
- 241001330502 Stephania Species 0.000 description 1
- 241000316342 Taxillus Species 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 208000020560 abdominal swelling Diseases 0.000 description 1
- 230000006578 abscission Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- -1 dampness Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- VNONINPVFQTJOC-ZGXDEBHDSA-N dioscin Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O VNONINPVFQTJOC-ZGXDEBHDSA-N 0.000 description 1
- CJNUQCDDINHHHD-APRUHSSNSA-N dioscin Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@H]6[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O CJNUQCDDINHHHD-APRUHSSNSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229950000193 oteracil Drugs 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- VNONINPVFQTJOC-UHFFFAOYSA-N polyphyllin III Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O VNONINPVFQTJOC-UHFFFAOYSA-N 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000009910 sargent gloryvine Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000004341 tarsal joint Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for preventing and treating gout of birds, and a preparation method and application thereof. The medicine composition contains active ingredients, wherein the active ingredients are prepared from rhizoma atractylodis, caulis sinomenii, radix clematidis, cortex phellodendri, rhizoma coptidis, polygonum cuspidatum, edible tulip, rhizoma dioscoreae septemlobae, rhizoma smilacis glabrae, magnolia officinalis, liquorice, mascot, camphor tree seed, vitamin A, potassium citrate and taurine. The composition has synergistic effect, and has effects of clearing heat, promoting blood circulation, nourishing liver and kidney, invigorating spleen, eliminating turbid urine, promoting diuresis, and removing dampness. Can be effectively used for preventing and treating gout of poultry, and has the advantages of wide raw material sources, safety, environmental protection, simple preparation process, low production cost and the like.
Description
Technical Field
The invention relates to the field of veterinary traditional Chinese medicines, in particular to a pharmaceutical composition for preventing and treating gout diseases of birds.
Background
Gout is a disease in which uric acid content in blood is remarkably increased due to excessive uric acid production or excretion disorder in poultry bodies, and further urate is deposited on joint capsules, joint circumferences, joint cartilages, thoracic and abdominal cavities, various visceral surfaces and other interstitial tissues. Clinically, chickens are mainly treated by visceral gout, and most of gout of geese is visceral gout combined with joint gout. Visceral gout manifests as inappetence, slow growth, hairiness, anemia, and white thin water sample of feces, mostly due to sporadic or batch death of renal failure. Joint gout, swelling of leg and toe tarsal joints and wing joints, lameness and bradykinesia, and some can not stand. The dissecting examination shows that the surfaces of organs such as visceral serous hearts, livers, lungs, spleens, intestines and the like are covered with a layer of white lime-like uric acid salt, and the kidneys are enlarged, pale in color and appear as plaque kidneys. White urate deposition can occur in unilateral or bilateral ureters. When the birds with joint gout cut the joints, pasty white viscous liquid flows out, and white urates are visible around the joints and even in muscle tissues.
At present, no good treatment method for the poultry pain exists. The traditional Chinese medicine has a great amount of clinical practice for treating gout, gradually forms a mature diagnosis and treatment means, has unique advantages in aspects of controlling the disease development of the gout of the poultry, reducing the adverse reaction rate and the like, can play roles of mechanism complementation, attenuation and synergism, but the pharmacological mechanism behind the traditional Chinese medicine is not clear, and limits the clinical application and popularization.
Disclosure of Invention
In order to solve the technical problems, the invention provides a traditional Chinese medicine composition for preventing and treating gout diseases of birds.
The traditional Chinese medicine composition contains active ingredients, wherein the active ingredients are prepared from rhizoma atractylodis, caulis sinomenii, radix clematidis, cortex phellodendri, rhizoma coptidis, polygonum cuspidatum, edible tulip, rhizoma dioscoreae septemlobae, rhizoma smilacis glabrae, cortex magnoliae officinalis, liquorice, herba mascot, camphor tree seeds, vitamin A, potassium citrate and sulfuric acid.
Further, the active ingredients are prepared from, by weight, 10-40 parts of rhizoma atractylodis, 5-30 parts of caulis sinomenii, 6-18 parts of radix clematidis, 5-30 parts of cortex phellodendri, 2-10 parts of rhizoma coptidis, 20-50 parts of polygonum cuspidatum, 5-25 parts of edible tulip, 5-20 parts of rhizoma dioscoreae, 5-25 parts of rhizoma smilacis glabrae, 5-30 parts of magnolia officinalis, 2-10 parts of liquorice, 20-50 parts of mascot, 20-30 parts of camphor tree seed, 1-9 parts of vitamin A, 3-12 parts of potassium citrate and 1-5 parts of taurine.
Further, the active ingredients are prepared from 15-30 parts by weight of rhizoma atractylodis, 10-25 parts by weight of caulis sinomenii, 10-16 parts by weight of radix clematidis, 10-20 parts by weight of cortex phellodendri, 4-8 parts by weight of rhizoma coptidis, 20-40 parts by weight of polygonum cuspidatum, 10-20 parts by weight of edible tulip, 10-16 parts by weight of rhizoma dioscoreae, 8-22 parts by weight of rhizoma smilacis glabrae, 10-24 parts by weight of cortex magnoliae officinalis, 4-8 parts by weight of liquorice, 30-45 parts by weight of mascot, 24-28 parts by weight of camphor tree seed, 3-6 parts by weight of vitamin A, 5-10 parts by weight of potassium citrate and 2-4 parts by weight of taurine.
Further, the active ingredients are prepared from 22 parts by weight of rhizoma atractylodis, 20 parts by weight of caulis sinomenii, 14 parts by weight of radix clematidis, 12 parts by weight of cortex phellodendri, 6 parts by weight of rhizoma coptidis, 30 parts by weight of polygonum cuspidatum, 18 parts by weight of edible tulip, 12 parts by weight of rhizoma dioscoreae, 18 parts by weight of rhizoma smilacis glabrae, 20 parts by weight of magnolia officinalis, 6 parts by weight of liquorice, 38 parts by weight of mascot, 26 parts by weight of camphor tree seed, 5 parts by weight of vitamin A, 7 parts by weight of potassium citrate and 3 parts by weight of taurine.
The invention also aims to provide a preparation method of a traditional Chinese medicine composition for preventing and treating gout of birds, which comprises the following steps:
(1) Weighing the raw materials of the medicines according to the weight ratio;
(2) Coarsely crushing the traditional Chinese medicine raw materials obtained in the step (1), soaking the raw materials in distilled water for 0.5h, decocting for 3 times, wherein the first time is 2 hours, the second time and the third time are respectively 1.0h, mixing the filtrates, and concentrating into thick paste for later use.
(3) Mixing the vitamin A and taurine weighed in the step (1) with proper amount of starch and dextrin uniformly, and then mixing with the thick paste in the step (2) uniformly to prepare the finished product.
The traditional Chinese medicine composition for preventing and treating the gout of the poultry, which is prepared by the preparation method, can be prepared into the following dosage forms: soluble powder, granule or oral liquid.
Furthermore, the traditional Chinese medicine composition powder for preventing and treating the gout disease of the poultry, which is prepared by the preparation method, has the medicine particle size below 70 microns.
The invention also provides application of the traditional Chinese medicine composition in preventing and treating gout diseases of birds.
In particular to a medicine for preventing and treating gout of birds by preparing the traditional Chinese medicine composition.
Furthermore, the invention also provides a poultry feed containing the traditional Chinese medicine composition.
The medicine has the advantages and beneficial effects that:
the traditional Chinese medicine composition is prepared by repeated verification and practice through a large number of clinical tests according to dialectical theory of Chinese veterinary prescriptions. The prescription of the invention combines pathogenesis and clinical symptoms of the gout disease of the poultry, and the treatment principle is an accurate prescription obtained by a great amount of clinical effect verification under the guidance of the diagnosis and treatment theory of the traditional Chinese medicine, thereby having good prevention and treatment effects on the gout disease of the poultry.
The fowl gout belongs to the categories of 'joint disease', 'arthralgia syndrome' in traditional Chinese medicine, the wind damp-heat arthralgia syndrome, the damp evil qi is remained without going, the heat is accumulated for a long time, and the fowl gout is infused into joints to cause qi and blood occlusion, blood vessels are not smooth, and the onset of the fowl gout is 5 important pathological links of the gout, namely heat, dampness, phlegm, deficiency and blood stasis. The traditional Chinese medicine diagnosis is that spleen deficiency and damp heat stasis are the principal of disease, spleen dysfunction and transportation are the principal of disease, damp heat phlegm stasis is the principal of disease, eating is favored by fat, sweet and greasy, long-term damp turbidity is generated internally, spleen dysfunction and transportation, invasion of exogenous evil, internal and external diseases are combined, damp heat stasis evil is blocked in tendons and bones, joint swelling and pain are seen, and liver and kidney are damaged after long-term blockage, and symptoms such as edema, hypodynamia and the like are presented. Traditional Chinese medicines for treating gout are selected from ancient times and mainly focused on the medicines for clearing heat and activating blood, strengthening spleen and purging turbid urine, nourishing liver and kidney, promoting diuresis and removing dampness and warming interior. The basic method for treating gout in traditional Chinese medicine is as follows: in the acute attack stage, the treatment is mainly to clear away heat and toxic materials, remove turbid urine, promote diuresis, remove arthralgia and dredge collaterals; in the rest period, the treatment mainly aims at strengthening spleen, eliminating dampness, tonifying liver and kidney, relaxing menstruation, dredging arthralgia and dredging collaterals. The occurrence of gout in birds is related to disharmony of viscera, disturbance of essence and endowment, and the like, and damp turbidity and toxin are pathogenic factors. The poultry gout belongs to bladder damp-heat and liver-gallbladder stagnation on middle veterinarian syndrome type classification, and is similar to sand and stone stranguria on middle veterinarian, and the principle of traditional Chinese medicine treatment is mainly to promote diuresis and remove dampness, clear heat, invigorate spleen and the like. The traditional Chinese medicine for promoting diuresis and removing dampness is suitable for treating stranguria and turbid urine (urinary system infection or calculus) and other symptoms besides edema, and general pharmacological actions include promoting urination and resisting bacteria, promoting bile flow and protecting liver, regulating immunity and the like, and can promote excretion of potassium, sodium, chlorine and other ions while promoting excretion of water. The traditional Chinese medicine has unique advantages in treating gout, which are different from western medicines, and the action mechanism is mainly focused on reducing uric acid level, inhibiting inflammatory reaction, resisting oxidative stress, regulating signal paths and the like.
In the patent of the invention, the giant knotweed and the rhizoma atractylodis are used as monarch drugs, wherein the giant knotweed has the effects of promoting diuresis and removing jaundice, clearing heat and detoxicating, removing blood stasis and relieving pain, and the resveratrol in the giant knotweed can inhibit the activity of xanthine oxidase and inhibit uric acid transport protein of kidney to doubly regulate and reduce the concentration of serum uric acid; rhizoma Atractylodis can dispel dampness and invigorate spleen, and has effects of removing pathogenic dampness, relieving exterior syndrome, dispelling pathogenic wind-dampness, and drying spleen and stomach dampness. Caulis Sinomenii, radix Clematidis, herba Reineckeae Carneae, cortex Phellodendri, and Coptidis rhizoma as ministerial drugs, wherein caulis Sinomenii has effects of dispelling pathogenic wind and dampness, dredging meridian, and relieving pain due to wind-dampness, joint swelling, and paralysis and itching, and has neutralizing effect on uric acid. The Chinese clematis root has the effects of dispelling wind and removing dampness, and activating collaterals and relieving pain, is mainly used for treating the symptoms of rheumatalgia, limb numbness, difficulty in flexing and extending, spasm of tendons and vessels and the like, and has the main effects of removing dampness, activating collaterals and relieving pain, and aims at the pathogenesis characteristics of pain, such as Yu Lao fatigue and pain caused by obstruction. The Reineckea carnea has the effects of moistening lung for arresting cough, reinforcing kidney and setting bone, and has the main effects of reinforcing kidney and setting bone in the invention patent. The berberine which is the main component in the coptis chinensis and the phellodendron barks deprives the catalytic action of xanthine oxidase, thereby playing a role in inhibiting the activity of xanthine oxidase and further reducing uric acid deposition. The edible tulip, the yam rhizome, the glabrous greenbrier rhizome, the officinal magnolia bark and the camphor tree are taken as adjuvant drugs, wherein the edible tulip has the functions of clearing heat and detoxicating, eliminating carbuncles and resolving hard mass, and is mainly used for treating furuncle, attacking toxin and breaking skin and resolving various toxins. Dioscorea opposite to the traditional Chinese medicine for treating the kidney function recovery can remove dampness, remove turbidity, expel wind and remove arthralgia, and dioscin in the yam opposite to the traditional Chinese medicine can effectively remove urate deposition and promote kidney function recovery. Rhizoma smilacis glabrae has the effects of promoting joint circulation, strengthening spleen and stomach, strengthening tendons and bones, removing rheumatism, promoting joint circulation and promoting water passage, is an essential drug for treating damp-heat stranguria with turbid urine, carbuncle swelling and plum sores, has an inhibiting effect on inflammatory reaction of urates, and can up regulate the expression of OAT1, organic cation transporter 2 (OCTN 2) and mRNA thereof in kidney tissues by inhibiting the activity of xanthine oxidase, so that urate deposition is obviously reduced. The magnolia officinalis has the effects of resolving dampness, removing stagnation, promoting qi circulation, relieving asthma, resolving food stagnation, dispelling pathogenic wind, relieving pain, and the effective components of phenols and alkalis of magnolia officinalis can promote the discharge of uric acid salts. Camphor fruit, fructus Laurae, with effects of dispelling cold and dampness, promoting qi circulation and relieving pain, and treating stomach cold and abdominal pain and swelling toxin. The invention has the main effects of dispelling wind and cold, eliminating dampness and detumescence. Glycyrrhrizae radix is used as guiding drug for clearing heat and detoxicating, eliminating phlegm and relieving cough. Can be used for treating stomach ache, abdominal pain, and gastrocnemius spasm pain.
Vitamin A can avoid uric acid excretion disorder caused by atrophy, keratinization and abscission of renal epithelial cells. Potassium citrate regulates water salt metabolism and acid-base balance in poultry. Taurine participates in regulating cell volume, provides a foundation for bile salt formation, plays an important role in the modulation of intracellular free calcium concentration, and plays an important role in protecting renal dysfunction and normal development. Taurine has the functions of diminishing inflammation, easing pain, maintaining the osmotic balance of the organism, regulating the digestion and absorption of lipid, increasing the solubility of lipid and cholesterol, relieving bile obstruction, reducing the cytotoxicity of certain free bile acid, inhibiting the formation of cholesterol stones, and increasing the bile flow and has the function of enhancing immunity. The medicines are combined to play roles of clearing heat and activating blood, nourishing liver and kidney, strengthening spleen and purging turbid urine, promoting diuresis and removing dampness, relieving swelling and treating stranguria, inducing resuscitation and removing stasis, purging pathogenic fire and expelling toxin, achieving the effects of inducing diuresis and relieving swelling and strengthening metabolism, and can effectively promote the excretion of the uric acid salt, avoid the damage of the deposition of the uric acid salt to organisms and have remarkable treatment effect on the poultry gout.
Compared with the prior art, the medicine has obvious effect of preventing and treating the gout of the poultry. The invention can further reduce the serum uric acid content of animals by adding vitamins, potassium citrate and taurine into the formula.
Detailed Description
The following examples are illustrative of the invention and are not intended to limit the scope of the invention.
EXAMPLE 1 preparation and use of the medicament of the invention
(1) Weighing the following raw materials by weight:
10 parts of rhizoma atractylodis, 5 parts of caulis sinomenii, 6 parts of radix clematidis, 5 parts of cortex phellodendri, 2 parts of rhizoma coptidis, 20 parts of polygonum cuspidatum, 5 parts of edible tulip, 5 parts of rhizoma dioscoreae, 5 parts of rhizoma smilacis glabrae, 5 parts of magnolia officinalis, 2 parts of liquorice, 20 parts of mascot, 20 parts of camphor tree seed, 1 part of vitamin A, 3 parts of potassium citrate and 1 part of taurine.
(2) Coarse pulverizing the raw materials of the traditional Chinese medicines with the weight, which are weighed in the step (1), soaking the raw materials in distilled water for 0.5h, decocting for 3 times, wherein the first time is 2 hours, the second time and the third time are respectively 1.0h, mixing the filtrates, and concentrating into thick paste for later use.
(3) Mixing vitamin A and taurine weighed in the step (1) with proper amount of starch and dextrin uniformly, and then mixing with the thick paste in the step (2) uniformly to prepare granules.
(4) The application method of the medicine comprises the following steps: the mixed drink is used for preventing and treating the gout of the poultry: 0.5kg of the traditional Chinese medicine is added into each 1 ton of water, and the water is drunk freely for 7 to 10 days.
EXAMPLE 2 preparation and use of the medicament of the invention
(1) Weighing the following raw materials by weight:
40 parts of rhizoma atractylodis, 30 parts of caulis sinomenii, 18 parts of radix clematidis, 30 parts of cortex phellodendri, 10 parts of rhizoma coptidis, 50 parts of polygonum cuspidatum, 25 parts of edible tulip, 20 parts of rhizoma dioscoreae, 25 parts of rhizoma smilacis glabrae, 30 parts of magnolia officinalis, 10 parts of liquorice, 50 parts of mascot, 30 parts of camphor tree, 9 parts of vitamin A, 12 parts of potassium citrate and 5 parts of taurine. Prepared and used as in example 1.
EXAMPLE 3 preparation and use of the medicament of the invention
(1) Weighing the following raw materials by weight:
15 parts of rhizoma atractylodis, 10 parts of caulis sinomenii, 10 parts of radix clematidis, 10 parts of cortex phellodendri, 4 parts of rhizoma coptidis, 20 parts of polygonum cuspidatum, 10 parts of edible tulip, 10 parts of rhizoma dioscoreae, 8 parts of rhizoma smilacis glabrae, 10 parts of magnolia officinalis, 4 parts of liquorice, 30 parts of mascot, 24 parts of camphor tree, 3 parts of vitamin A, 5 parts of potassium citrate and 2 parts of taurine. Prepared and used as in example 1.
EXAMPLE 4 preparation and use of the medicament of the invention
(1) Weighing the following raw materials by weight:
30 parts of rhizoma atractylodis, 25 parts of caulis sinomenii, 16 parts of radix clematidis, 20 parts of cortex phellodendri, 8 parts of rhizoma coptidis, 40 parts of polygonum cuspidatum, 20 parts of edible tulip, 16 parts of rhizoma dioscoreae, 22 parts of rhizoma smilacis glabrae, 24 parts of magnolia officinalis, 8 parts of liquorice, 45 parts of mascot, 28 parts of camphor tree, 6 parts of vitamin A, 10 parts of potassium citrate and 4 parts of taurine. Prepared and used as in example 1.
EXAMPLE 5 preparation and use of the medicament of the invention
(1) Weighing the following raw materials by weight:
22 parts of rhizoma atractylodis, 20 parts of caulis sinomenii, 14 parts of radix clematidis, 12 parts of cortex phellodendri, 6 parts of rhizoma coptidis, 30 parts of polygonum cuspidatum, 18 parts of edible tulip, 12 parts of rhizoma dioscoreae, 18 parts of rhizoma smilacis glabrae, 20 parts of magnolia officinalis, 6 parts of liquorice, 38 parts of mascot, 26 parts of camphor tree, 5 parts of vitamin A, 7 parts of potassium citrate and 3 parts of taurine. Prepared and used as in example 1.
Comparative example 1
A traditional Chinese medicine composition for preventing and treating gout of birds comprises the following components in parts by weight: 2 parts of glabrous greenbrier rhizome, 2 parts of pagodatree flower, 2 parts of climbing fern spore, 1.5 parts of akebia stem, 1 part of coptis chinensis, 2 parts of liquorice, 1 part of astragalus mongholicus, 1 part of hawthorn and 1 part of medicated leaven.
The preparation method of the traditional Chinese medicine composition for preventing and treating the gout of the poultry comprises the following steps:
weighing the traditional Chinese medicine according to the proportion, coarsely crushing, extracting for 2 times by a water extraction method, extracting for 1.5 hours at 75 ℃ for 20 times of water for the first time, extracting for 1.0 hour at 75 ℃ for 10 times of water for the second time, combining the two extracting solutions, filtering, and concentrating the filtrate under reduced pressure and vacuum to 1g/mL to obtain the traditional Chinese medicine.
Comparative example 2
A traditional Chinese veterinary medicine for treating gout comprises the following components in parts by weight: 7 parts of catechu, 7 parts of frankincense, 12 parts of ash bark, 12 parts of amur corktree bark and 12 parts of swordlike atractylodes rhizome.
The preparation method of the traditional Chinese veterinary medicine for treating gout comprises the following steps: weighing the traditional Chinese medicines in parts by weight, coarsely crushing, adding 6 times of 60% ethanol for extraction for 3 times, each time for 1h, combining the extracting solutions, filtering, concentrating the filtrate under reduced pressure to obtain a relative density of 1.05, adding a proper amount of auxiliary materials, and preparing into granules.
Comparative example 3
The medicine for treating acute gouty arthritis comprises the following components in parts by weight: 20 parts of honeysuckle, 20 parts of sargentgloryvine stem, 12 parts of Indian iphigenia bulb, 20 parts of clematis root, 20 parts of coix seed, 20 parts of medicinal cyathula root, 30 parts of lysimachia christinae hance, 20 parts of yam rhizome, 30 parts of glabrous greenbrier rhizome, 20 parts of ash bark, 20 parts of grifola frondosa, 20 parts of caulis sinomenii, 15 parts of stephania tetrandrae, 20 parts of alisma orientale, 10 parts of fructus Litseae, 9 parts of rhizoma pinelliae preparata, 20 parts of plantain herb, 9 parts of safflower, 9 parts of costustoot, 10 parts of cassia seed, 6 parts of long pepper, 15 parts of plantain seed, 10 parts of amur corktree bark, 12 parts of rhizoma corydalis, 12 parts of red paeony root, 12 parts of giant knotweed rhizome, 15 parts of swordlike atractylodes rhizome, 10 parts of clematis root, 12 parts of Chinese taxillus twig, 6 parts of rhubarb, 12 parts of tree peony root, 12 parts of root of pubescent angelica and 6 parts of liquorice.
The preparation method of the medicine for treating acute gouty arthritis comprises the following steps: weighing the traditional Chinese medicines in parts by weight, extracting with 10 times of water twice for 2 hours each time, mixing the extracting solutions, filtering, and concentrating the filtrate under reduced pressure until the relative density is 1.2.
Comparative example 4
The traditional Chinese medicine for treating gouty arthritis comprises the following components in parts by weight: 10 parts of amur corktree bark, 10 parts of swordlike atractylodes rhizome, 30 parts of glabrous greenbrier rhizome, 10 parts of liquoric root, 15 parts of Chinese clematis root, 10 parts of red paeony root, 15 parts of giant knotweed rhizome, 10 parts of Chinese angelica, 8 parts of Indian iphigenia bulb, 10 parts of pubescent angelica root, 15 parts of pilose asiabell root and 10 parts of wine rhubarb.
The preparation method of the traditional Chinese medicine for treating gouty arthritis comprises the following steps: weighing the traditional Chinese medicines in parts by weight, extracting with 10 times of water twice for 2 hours each time, mixing the extracting solutions, filtering, and concentrating the filtrate under reduced pressure until the relative density is 1.2.
Comparative example 5
The composition comprises the following components in parts by weight: 22 parts of rhizoma atractylodis, 20 parts of caulis sinomenii, 14 parts of radix clematidis, 12 parts of cortex phellodendri, 6 parts of coptis chinensis, 30 parts of polygonum cuspidatum, 18 parts of edible tulip, 12 parts of rhizoma dioscoreae, 18 parts of rhizoma smilacis glabrae, 20 parts of magnolia officinalis, 6 parts of liquorice, 38 parts of mascot, and 26 parts of camphor tree.
The preparation method of comparative example 5 is:
(1) Weighing the following raw materials by weight:
10 parts of rhizoma atractylodis, 5 parts of caulis sinomenii, 6 parts of radix clematidis, 5 parts of cortex phellodendri, 2 parts of rhizoma coptidis, 20 parts of polygonum cuspidatum, 5 parts of edible tulip, 5 parts of rhizoma dioscoreae, 5 parts of rhizoma smilacis glabrae, 5 parts of magnolia officinalis, 2 parts of liquorice, 20 parts of mascot, and 20 parts of camphor tree.
(2) Coarse pulverizing the raw materials of the traditional Chinese medicines with the weight, which are weighed in the step (1), soaking the raw materials in distilled water for 0.5h, decocting for 3 times, wherein the first time is 2 hours, the second time and the third time are respectively 1.0h, mixing the filtrates, and concentrating into thick paste for later use.
(3) Adding proper amount of starch and dextrin into the thick paste in the step 2, mixing and preparing into particles.
In order to show the prevention and treatment effect of the medicine on the gout disease of the poultry, the clinical curative effect observation test is carried out on the medicine, and the beneficial effects of the medicine are further illustrated by test examples.
Test example 1
In order to examine the effect of the drug of the invention on uric acid reduction, the test of potassium oxazinate to hyperuricemia in mice was adopted in animal laboratories of the national institute of motion protection in Dabei in 2020.
1 test drug and apparatus
1.1 test article: the medicines prepared in examples 1-5, the medicines prepared in comparative examples 1-5, allopurinol, gout-relieving capsules, physiological saline, potassium oxazinate, a mouse stomach-lavage needle, a syringe, a blood collection tube and a centrifuge.
1.2 test animals: kunming mice
2 test method
The new Kunming mice with the weight of 16-18g were selected and randomly divided into 14 test groups after 2 days of normal feeding, 10 test groups, test 1 group-test 5 group are respectively the drug of the invention example 1 to example 5, test 6 group-test 10 group are respectively the comparative example 1 to comparative example 5, test 11 ancestor is gout peace capsule group, test 12 group is allopurinol group (positive drug group), test 13 group is model group, and test 14 group is normal group. The same volume of physiological saline was infused in the test 13 group and the test 14 group, and the drugs prepared in examples 1 to 5 of the drugs according to the present invention were administered in the test 1 group to the test 5 group, respectively, and the drugs prepared in examples 1 to 5 were administered in 1mL of a solution corresponding to 1g of the drug according to the present invention, and in 20g/kg, 1 time of gastric administration was administered daily in the morning, followed by 5 days of continuous administration. Test 6 to 10 groups were respectively administered with the drugs prepared in comparative examples 1 to 5, and the drugs prepared in comparative examples 1 to 5 were administered 1mL of a solution corresponding to 1g of the drug of comparative example, 1 time a day at the morning by gavage, and 5 days continuously. The gouning control drug was administered to the trial 11 group at a dose of 20g/kg, 1 time per day by gavage in the morning for 5 consecutive days. The control drug allopurinol was administered to the test group 12 at a dose of 0.02g/kg 1 time per day by gavage in the morning for 5 consecutive days. The last day of administration 1 hour before, test 1 group to test 13 group with potassium oxazinate 650mg/kg intraperitoneal injection molding, test 14 group injection 0.6% sodium carboxymethyl cellulose, 1.5mL after 1 hour, orbital vein blood collection, room temperature standing for 1 hour, 4000rmp centrifugation for 10min, supernatant, phosphotungstic acid reduction method detection serum uric acid level.
Principle of detecting serum uric acid level by phosphotungstic acid method reduction method: uric acid in deproteinized blood filtrate is oxidized into allantoin and carbon dioxide by tungstic acid in alkaline solution, phosphotungstic acid is reduced into tungsten blue in the reaction, the production amount of tungsten blue is in direct proportion to the uric acid content in reaction liquid, and colorimetric determination can be carried out.
Test reagent and test for detecting serum uric acid level by phosphotungstic acid method reduction method
3 operation steps
3.1 test reagents
3.1.1 phosphotungstic acid stock solution: 50g of sodium tungstate was weighed, dissolved in about 400ml of distilled water, 40ml of concentrated phosphoric acid and glass particles were added, boiled water was returned to cool to room temperature, diluted to 1 liter with distilled water, and stored in a brown reagent bottle.
3.1.2 phosphotungstic acid application liquid: 10ml of the phosphotungstic acid stock solution was taken and diluted to 100ml with distilled water.
3.1.3 0.3mol/L sodium tungstate solution: 100g of sodium tungstate (Na 2WO42H2O, MW 329.36) was weighed out, dissolved in distilled water and diluted to 1 liter.
3.1.4 0.33mol/L sulfuric acid: 18.5ml of concentrated sulfuric acid was taken and added to 500ml of distilled water, followed by dilution with distilled water to 1 liter.
3.1.5 tungstic acid reagent: 50ml of a 0.3mol/L sodium tungstate solution, 0.05ml of concentrated phosphoric acid and 50ml of 0.33mol/L sulfuric acid were added to 800ml of distilled water, and the mixture was mixed well.
3.1.6 lmol/L sodium carbonate solution: 10.6g of anhydrous sodium phosphate solution was weighed in distilled water, diluted to 1 liter and placed in a plastic flask, and if cloudy, filtered for use.
3.1.7 6.0mol/L uric acid standard stock solution: 60mg of lithium carbonate (AR) is dissolved in 40ml of distilled water and heated to 60 ℃ to be completely dissolved, 100.9mg of uric acid (MW 168.11) is accurately weighed and dissolved in the lithium carbonate solution, the solution is cooled and placed at room temperature, transferred into a 1000ml volumetric flask, diluted to a scale with distilled water and stored in a brown flask.
3.2 test operation method
Taking 16 test tubes with the scale of 16mm multiplied by 00mm, adding 4.5ml of tungstic acid reagent into each test tube, respectively adding 0.5ml of serum of test 1-14 into test tubes with the scale of 1-116 and the scale of 1-14, adding 0.5ml of standard application liquid into test tubes with the scale of 15, adding 0.5ml of distilled water into test tubes with the scale of 16, uniformly mixing, standing for 10min, centrifugally precipitating the test tubes with the scale of 1-14, respectively taking 2.5ml of supernatant liquid with the scale of 1-16, respectively adding 0.5ml of sodium carbonate solution, uniformly mixing, standing for 10min, adding 0.5ml of phosphotungstic acid application liquid, uniformly mixing, standing for 20min, zeroing the solution of test tubes with the scale of 16 with a blank tube at the wavelength of 660nm by using a spectrophotometer, and reading the absorbance of each tube. The procedure is as in Table 1
TABLE 1 operation of phosphotungstic acid reduction method for detecting serum uric acid
Serum uric acid calculation: serum uric acid μmol/l=assay tube absorbance/standard tube absorbance×300
4 test results and conclusions
TABLE 2 Effect of the inventive drug on hyperuricemia mice serum uric acid caused by Potassium Oxonate
As can be seen from Table 2, compared with the model control group, the medicine of the invention, the comparative example medicine and the positive control medicine, and the medicine for treating gout, fengshuning capsule, which is commonly used in the market, can remarkably reduce serum uric acid of mice. The effect of the medicine for reducing serum uric acid is stronger than that of the medicine for treating gout, namely allopurinol, which is a comparative example medicine and a positive control medicine. Compared with the test group 10, the test group 5 has better uric acid reducing effect on the serum of mice, that is, the medicine of the example 5 has better uric acid reducing effect on the serum of mice than the medicine of the comparative example 5, which shows that three substances of vitamin A, potassium citrate and sulfuric acid have synergistic effect on the uric acid reducing effect on the serum of mice of the traditional Chinese medicine composition. The test 5 groups of the medicine have the best uric acid reducing effect on the serum of mice, and are the optimal prescription of the invention.
Test example 2
In 8 months 2019, 50000 laying hen houses raised by Jiangsu Wang Mou are characterized by sudden enlargement of joints of action legs, slow action, lameness, anorexia, diarrhea and the like, and the veterinary clinic diagnosis shows that the chickens are gout diseases, and the medicines prepared in the example 5 are used for treating and dosing a plurality of chicken houses with the disease, and the medicines sold in the market for treating gout are used for treating for 10 days. After half a month, the service staff return visit, and more than 90% of chickens in the chicken house treated by the medicament prepared in the example 5 are recovered to be normal, and the mental state is good. And 60% of chickens in another henhouse treated by the medicines sold in the market for treating gout are recovered to be normal, and some chickens are accompanied with red and swollen joints. The medicine feedback of Wang Mou shows that the medicine has good treatment effect on chicken gout.
The foregoing is merely a preferred embodiment of the present invention, and it should be noted that it will be apparent to those skilled in the art that several modifications and variations can be made without departing from the technical principle of the present invention, and these modifications and variations should also be regarded as the scope of the invention.
Claims (4)
1. The medicine composition for preventing and treating the gout of the poultry is characterized by being prepared from 10-40 parts of rhizoma atractylodis, 5-30 parts of caulis sinomenii, 6-18 parts of radix clematidis, 5-30 parts of cortex phellodendri, 2-10 parts of rhizoma coptidis, 20-50 parts of polygonum cuspidatum, 5-25 parts of edible tulip, 5-20 parts of rhizoma dioscoreae, 5-25 parts of rhizoma smilacis glabrae, 5-30 parts of magnolia officinalis, 2-10 parts of liquorice, 20-50 parts of mascot, 20-30 parts of camphor tree seed, 1-9 parts of vitamin A, 3-12 parts of potassium citrate and 1-5 parts of taurine.
2. The pharmaceutical composition for preventing and treating gout of poultry according to claim 1, wherein the composition is prepared from 15-30 parts of rhizoma atractylodis, 10-25 parts of caulis sinomenii, 10-16 parts of radix clematidis, 10-20 parts of cortex phellodendri, 4-8 parts of rhizoma coptidis, 20-40 parts of polygonum cuspidatum, 10-20 parts of edible tulip, 10-16 parts of rhizoma dioscoreae, 8-22 parts of rhizoma smilacis glabrae, 10-24 parts of magnolia officinalis, 4-8 parts of liquorice, 30-45 parts of mascot, 24-28 parts of camphor tree seed, 3-6 parts of vitamin A, 5-10 parts of potassium citrate and 2-4 parts of taurine.
3. The pharmaceutical composition for preventing and treating gout of poultry according to claim 2, wherein the composition is prepared from 22 parts of rhizoma atractylodis, 20 parts of caulis sinomenii, 14 parts of radix clematidis, 12 parts of cortex phellodendri, 6 parts of rhizoma coptidis, 30 parts of polygonum cuspidatum, 18 parts of edible tulip, 12 parts of rhizoma dioscoreae septemlobae, 18 parts of rhizoma smilacis glabrae, 20 parts of magnolia officinalis, 6 parts of liquorice, 38 parts of herba reineckiae, 26 parts of camphor tree, 5 parts of vitamin A, 7 parts of potassium citrate and 3 parts of taurine.
4. Use of a pharmaceutical composition for preventing and treating gout in birds according to any one of claims 1 to 3 in the preparation of a medicament for preventing and treating gout in birds.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110890080.2A CN113491743B (en) | 2021-08-04 | 2021-08-04 | Pharmaceutical composition for preventing and treating gout of birds and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110890080.2A CN113491743B (en) | 2021-08-04 | 2021-08-04 | Pharmaceutical composition for preventing and treating gout of birds and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113491743A CN113491743A (en) | 2021-10-12 |
| CN113491743B true CN113491743B (en) | 2024-03-12 |
Family
ID=77996011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110890080.2A Active CN113491743B (en) | 2021-08-04 | 2021-08-04 | Pharmaceutical composition for preventing and treating gout of birds and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113491743B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116139231A (en) * | 2022-12-26 | 2023-05-23 | 珠海脉氪生物科技有限公司 | Compositions for specific dissolution of urate crystals in joints |
-
2021
- 2021-08-04 CN CN202110890080.2A patent/CN113491743B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 中医药治疗痛风的研究进展;汪元;刘健;;中国临床保健杂志;-(04);444页右栏第2段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113491743A (en) | 2021-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011009230A1 (en) | Pharmaceutical for treating idiopathic edema and preparation methods thereof | |
| EP3406258B1 (en) | Medicament for use in treating gout | |
| CN113491743B (en) | Pharmaceutical composition for preventing and treating gout of birds and preparation method and application thereof | |
| CN105943958A (en) | Inonotus obliquus composite solid particles for treating gout and preparing method thereof | |
| CN103705796B (en) | A kind of pharmaceutical composition for the treatment of diarrhoea and preparation method thereof | |
| CN101209296A (en) | Chinese medicinal granule with worm-expelling liver-caring, hemostasis and dysentery-stopping efficacy | |
| CN104474231A (en) | Traditional Chinese medicine preparation for treating cute red eyes, sore pain and difficultly-opened eyes with bitter tears and preparation method of traditional Chinese medicine preparation | |
| CN104548016A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating hyperuricemia | |
| CN114712478B (en) | Traditional Chinese medicine composition for treating intestinal diseases, preparation and preparation method thereof | |
| CN104352797A (en) | Traditional Chinese medicine for treating advanced lung cancer and application of traditional Chinese medicine | |
| CN101468056B (en) | Chinese medicine preparation for treating enteritis, diarrhea, and red-white dysentery | |
| CN104491344A (en) | Use of traditional Chinese medicine preparation in preparing medicines for treating bulging, red, swelling and pain symptoms of eyes | |
| CN109125631A (en) | Chinese medicine composition and preparation method thereof with liver kidney regulatory function | |
| CN116832105B (en) | Traditional Chinese medicine preparation for protecting kidney and promoting urination and preparation method thereof | |
| CN105288048B (en) | Traditional Chinese medicine compound oral liquid for preventing and treating calf diarrhea | |
| CN109125427B (en) | Penyanjing suppository and preparation method thereof | |
| CN114931214B (en) | Chinese herbal medicine composition for improving hearing impairment and preparation method and application thereof | |
| CN107050359A (en) | Treat strong medicine preparation of chronic pelvic inflammatory disease sequelae and preparation method thereof | |
| CN106109617A (en) | A kind of refined even electuary and preparation method thereof treating diabetes | |
| CN117883530A (en) | Traditional Chinese medicine composition for treating animal diarrhea and preparation method thereof | |
| CN101209319A (en) | Compound Chinese medicinal granule with heat-clearing and detoxication, damp-clearing and diuresis-promoting efficacy | |
| CN112138110A (en) | Preparation method of 'Xiaoyao shortbread' compound preparation and application of 'Xiaoyao shortbread' compound preparation in preparation of medicines for preventing or treating fatigue | |
| CN112386660A (en) | Traditional Chinese veterinary medicine composition for treating acute and chronic kidney failure of dogs and cats and preparation method thereof | |
| CN116832105A (en) | Traditional Chinese medicine preparation for protecting kidney and promoting urination and preparation method thereof | |
| CN117442688A (en) | Pharmaceutical composition for reducing uric acid and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220711 Address after: 101407 Beijing city Huairou District Yanqi Economic Development Zone No. 10 North Street Applicant after: Beijing Dabeinong Animal Health Care Technology Co.,Ltd. Applicant after: Shaoshan Da Bei Nong Animal Pharmaceutical Co., Ltd. Address before: 101407 Beijing city Huairou District Yanqi Economic Development Zone No. 10 North Street Applicant before: Beijing Dabeinong Animal Health Care Technology Co.,Ltd. Applicant before: Shaoshan Dabeinong Animal Medicine Co.,Ltd. Applicant before: BEIJING DABEINONG TECHNOLOGY GROUP Co.,Ltd. |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |